ClinicalTrials.gg
CompletedNCT00044044Updated Apr 17, 2014Results posted

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

A Phase 2 interventional study of Lurasidone 20 mg and Lurasidone 40mg in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 34 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-04-17.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
11th of 39
356 · median 149
Started
2002
with 1 other
Phase 2
5 of 39
none open now
Registered
1st of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 11th largest by enrollment, is one of 2 that started in 2002, is one of 5 in phase 2, and was the 1st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Latuda
  • Lurasidone
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a primary diagnosis of schizophrenia
  • The patient has been hospitalized with acute or relapsing schizophrenia within 3 weeks of screening
  • The patient has had a duration of illness of at least one year.
  • The patient has a BPRS score of at least 42 at baseline and a score of at least 4 in two or more items of the positive symptom subcluster on the PANSS
  • The patient is able to remain off antipsychotic medication for a 4 day

Exclusion criteria

Exclusion criteria:

  • The patient has had psychiatric hospitalizations other than current hospitalizations within 1 month prior to screening.
  • The patient is considered treatment resistant-Substance abuse-Prolactin level of > 200 ng/mL at baseline
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Lurasidone 20 mg

    Lurasidone 20 mg tablets

    Drug: Lurasidone 20 mg

  • Experimental
    Lurasidone 40 mg

    Lurasidone 40 mg tablets

    Drug: Lurasidone 40mg

  • Experimental
    Lurasidone 80 mg

    Lurasidone 2 40 mg tablets

    Drug: Lurasidone 80 mg

  • Active comparator
    Haloperidol 10mg

    Haloperidol 10mg tablets

    Drug: Haloperidol 10mg

  • Placebo comparator
    Placebo

    Matching Placebo to Lurasidone and Haloperidol

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale)Total Score

    The BPRS consists of 18 ordered categorical items (from "not present" to "extremely severe," on a 1- to 7-point scale), each developed to assess patient symptomatology in a relatively discrete symptom area. The BPRS will be extracted from the PANSS by adding the scores of the 18 items (P2 to P7, N1, N2, and G1 to G10) of the PANSS and will not be assessed separately. The minimum score on the BPRS is 18 and the maximum is 126. The higher number indicates a worsening of schizophrenia.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores

    The PANSS Positive and Negative Syndrome Scale)is a 30-item scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. Each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme). Scores range from 30-210 with higher scores representing a worsening of schizophrenia.

    Time frame: Baseline and 6 weeks

  2. Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores

    The CGI Severity (CGI-S) assesses the severity of illness of the patient relative to the particular population on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and 6 weeks

  3. Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores

    The MADRS is a 10-item rating scale that assesses apparent and reported sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

    Time frame: Baseline and 6 weeks

07

Results

Posted Apr 12, 2011

Participant flow

Participant flow — Overall Study
Milestone20 mg40 mg80 mg10 mg HaloperidolPlacebo
Started7169717372
Completed2728312936
Not completed4441404436

Outcome measures

PrimaryChange From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale)Total Score

The BPRS consists of 18 ordered categorical items (from "not present" to "extremely severe," on a 1- to 7-point scale), each developed to assess patient symptomatology in a relatively discrete symptom area. The BPRS will be extracted from the PANSS by adding the scores of the 18 items (P2 to P7, N1, N2, and G1 to G10) of the PANSS and will not be assessed separately. The minimum score on the BPRS is 18 and the maximum is 126. The higher number indicates a worsening of schizophrenia.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale)Total Score
units on a scale20 mg40 mg80 mg10 mg HaloperidolPlacebo
Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale)Total Score-5.0 ± 1.38-5.2 ± 1.44-8.0 ± 1.40-9.8 ± 1.37-7.9 ± 1.38
Statistical analysis
  • 20 mg vs 40 mg vs 80 mg vs 10 mg Haloperidol vs Placebo · ANCOVA · p = <0.05
SecondaryChange From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores

The PANSS Positive and Negative Syndrome Scale)is a 30-item scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. Each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme). Scores range from 30-210 with higher scores representing a worsening of schizophrenia.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores
units on a scale20 mg40 mg80 mg10 mg HaloperidolPlacebo
Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores-7.1 ± 2.31-7.2 ± 2.42-13.6 ± 2.34-16.0 ± 2.29-12.3 ± 2.32
Statistical analysis
  • 20 mg vs 40 mg vs 80 mg vs 10 mg Haloperidol vs Placebo · ANCOVA · p = <0.05
SecondaryChange From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores

The CGI Severity (CGI-S) assesses the severity of illness of the patient relative to the particular population on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores
units on a scale20 mg40 mg80 mg10 mg HaloperidolPlacebo
Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores-0.5 ± 0.11-0.4 ± 0.12-0.8 ± 0.12-0.8 ± 0.12-0.7 ± 0.11
Statistical analysis
  • 20 mg vs 40 mg vs 80 mg vs 10 mg Haloperidol vs Placebo · ANCOVA · p = <0.05
SecondaryChange From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores

The MADRS is a 10-item rating scale that assesses apparent and reported sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on scale
Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores
units on scale20 mg40 mg80 mg10 mg HaloperidolPlacebo
Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores-1.3 ± 0.97-1.1 ± 1.02-2.5 ± 0.98-2.7 ± 0.96-1.9 ± 0.97
Statistical analysis
  • 20 mg vs 40 mg vs 80 mg vs 10 mg Haloperidol vs Placebo · ANCOVA · p = <0.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20 mg—4/71 (5.6%)49/71 (69%)
40 mg—9/67 (13.4%)51/67 (76.1%)
80 mg—3/71 (4.2%)51/71 (71.8%)
10 mg Haloperidol—5/72 (6.9%)58/72 (80.6%)
Placebo—7/72 (9.7%)50/72 (69.4%)
Most frequent serious events
Most frequent serious events
Event20 mg40 mg80 mg10 mg HaloperidolPlacebo
SchizophreniaPsychiatric disorders2/718/672/713/724/72
Suicidal IdeationPsychiatric disorders1/711/670/712/721/72
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/710/670/710/720/72
AnxietyPsychiatric disorders0/710/671/711/720/72
Grand Mal ConvulsionNervous system disorders0/710/670/710/721/72
Abnormal BehaviorPsychiatric disorders0/710/670/711/720/72
AgitationPsychiatric disorders0/710/670/710/721/72
Most frequent other events
Showing 10 of 26
Most frequent other events
Event20 mg40 mg80 mg10 mg HaloperidolPlacebo
HeadacheNervous system disorders15/7116/6717/7114/7224/72
SedationNervous system disorders8/7111/6715/7115/726/72
AkathisiaNervous system disorders4/719/6713/7114/727/72
NauseaGastrointestinal disorders8/717/6713/714/728/72
Extrapyramidal DisorderNervous system disorders3/714/674/7113/723/72
VomitingGastrointestinal disorders5/715/6712/714/725/72
InsomniaPsychiatric disorders6/715/674/7112/725/72
AgitationPsychiatric disorders7/719/673/713/723/72
AnxietyPsychiatric disorders2/719/672/719/724/72
FatigueGeneral disorders5/712/679/717/723/72

Baseline characteristics

Age, Continuous
Age, Continuous(years)20 mg40 mg80 mg10 mg HaloperidolPlaceboTotal
Mean40.7 ± 10.542.0 ± 10.942.2 ± 8.340.0 ± 10.541.0 ± 9.741.2 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)20 mg40 mg80 mg10 mg HaloperidolPlaceboTotal
Female202119141791
Male5146525855262
08

Study locations

34 sites
  • Birmingham Psychiatry Pharmaceutical
    Birmingham, Alabama 35209, United States
  • Institute for Psychopharmacology Research
    Cerritos, California 90703, United States
  • CNS Network
    Garden Grove, California 92845, United States
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Optimum Health Services
    La Mesa, California 91942, United States
  • University of California, Irvine
    Orange, California 92868, United States
  • Affiliated Research Institute
    San Diego, California 92108, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • California Neuropsychopharmacolgoy Clinical Research Insitute
    San Diego, California 92126, United States
  • Comprehensive Neuroscience. Inc.
    Washington, District of Columbia 20016, United States
  • Comprehensive Neuroscience. Inc.
    Melbourne, Florida 32935, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Coordinated Research of Florida, Inc.
    Winter Park, Florida 32789, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Hawaii Research Center
    Honolulu, Hawaii 96826, United States
  • Alexian Brothers Behavioral Health Hospital
    Hoffman Estates, Illinois 60194, United States
  • American Medical Research
    Oakbrook, Illinois 60523, United States
  • Centers for Behavioral Health, LLC
    Rockville, Maryland 20850, United States
  • Lake Mead Hospital
    North Las Vegas, Nevada 89030, United States
  • Comprehensive Clinical Research CNS, PC
    Clementon, New Jersey 08021, United States
  • ClinSearch, Inc.
    Kenilworth, New Jersey 07033, United States
  • Psychiatric Professional Services Inc
    Cincinnati, Ohio 45267, United States
  • Quantum Clinical Services Group
    Philadelphia, Pennsylvania 19139, United States
  • Albert Einstein Medical Center - Dept. of Psychiatry
    Philadelphia, Pennsylvania 19141, United States
  • Community Clinical Research
    Austin, Texas 78756, United States
  • FutureSearch Trials
    Austin, Texas 78756, United States
  • Claghorn Lesem Research Clinic, Inc.
    Bellaire, Texas 77401, United States
  • St. Paul Medical Center
    Dallas, Texas 75235, United States
  • University Hills Clinical Research
    Dallas, Texas 75235, United States
  • CNS, Inc.
    Falls Church, Virginia 22041, United States
  • Northwest Clinical Research Center
    Belleview, Washington 98004, United States
  • Medstream, Inc.
    Milwaukee, Wisconsin 53210, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002, a primary completion of May 2003 and a completion of May 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 7 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2002
First posted
Aug 20, 2002
Start
Jul 2002
Primary completionActual
May 2003
CompletionActual
May 2003
Results first posted
Apr 12, 2011
Last update
Apr 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00044044
Responsible party
Sponsor
First posted
Aug 20, 2002
Start date
Jul 2002
Primary completion
May 2003
Completion
May 2003
Results posted
Apr 12, 2011
Last update
Apr 17, 2014

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion